Insider Transactions in Q1 2025 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2025
|
Roy D. Baynes |
SELL
Open market or private sale
|
Direct |
16,000
-34.04%
|
$320,000
$20.0 P/Share
|
|
Jan 23
2025
|
Roy D. Baynes |
BUY
Exercise of conversion of derivative security
|
Direct |
16,000
+25.4%
|
$272,000
$17.5 P/Share
|
|
Jan 22
2025
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,437
-2.85%
|
$46,303
$19.46 P/Share
|
|
Jan 22
2025
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,584
-1.47%
|
$28,512
$18.94 P/Share
|
|
Jan 22
2025
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,437
-3.07%
|
$46,303
$19.46 P/Share
|
|
Jan 22
2025
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
10,736
-2.97%
|
$203,984
$19.46 P/Share
|
|
Jan 22
2025
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
925
-1.68%
|
$16,650
$18.94 P/Share
|
|
Jan 22
2025
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
865
-1.16%
|
$15,570
$18.94 P/Share
|
|
Jan 06
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
440
-0.73%
|
$7,920
$18.76 P/Share
|
|
Jan 03
2025
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,066
-3.34%
|
$39,254
$19.1 P/Share
|